MCID: RDC006
MIFTS: 45

Red Cell Aplasia

Categories: Blood diseases, Rare diseases

Aliases & Classifications for Red Cell Aplasia

Summaries for Red Cell Aplasia

MalaCards based summary : Red Cell Aplasia is related to transient erythroblastopenia of childhood and large granular lymphocyte leukemia. An important gene associated with Red Cell Aplasia is EPO (Erythropoietin), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Phenytoin and Sirolimus have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and t cells, and related phenotypes are Increased shRNA abundance and digestive/alimentary

Related Diseases for Red Cell Aplasia

Diseases related to Red Cell Aplasia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 438)
# Related Disease Score Top Affiliating Genes
1 transient erythroblastopenia of childhood 34.4 KITLG EPO
2 large granular lymphocyte leukemia 31.6 STAT3 IL2RA
3 chronic graft versus host disease 31.0 IL2RA ALB
4 pure red-cell aplasia 30.9 TRB TF STAT3 IL2RA IL2 HLA-DRB1
5 deficiency anemia 30.7 TF EPO ALB
6 hematopoietic stem cell transplantation 30.6 IL2 HLA-B HLA-A
7 end stage renal failure 30.5 TF EPO ALB
8 autoimmune enteropathy 30.5 STAT3 IL2RA
9 autoimmune hepatitis 30.2 HLA-DRB1 HLA-DQB1 HLA-A
10 sclerosing cholangitis 30.2 HLA-DRB1 HLA-B ALB
11 cholangitis 30.2 HLA-DRB1 HLA-B ALB
12 acute disseminated encephalomyelitis 30.1 HLA-DRB1 HLA-DQB1 HLA-B
13 kwashiorkor 30.0 TF ALB
14 marasmus 29.9 TF ALB
15 mumps 29.9 IL2RA IL2 HLA-DRB1
16 essential thrombocythemia 29.9 STAT3 IFNA1 EPO
17 b-cell expansion with nfkb and t-cell anergy 29.9 TRB IL2RA IL2
18 sarcoidosis 1 29.8 IL2RA IL2 HLA-DRB1
19 myeloma, multiple 29.7 STAT3 IL2 IFNA1 EPO ALB
20 hairy cell leukemia 29.7 IL2RA IL2 IFNA1
21 autoimmune lymphoproliferative syndrome 29.7 STAT3 IL2RA IL2
22 herpes zoster 29.6 IL2 HLA-B HLA-A
23 graft-versus-host disease 29.5 IL2 HLA-DRB1 HLA-DQB1 HLA-B HLA-A
24 rubella 29.5 HLA-DRB1 HLA-DQB1 HLA-B HLA-A
25 systemic lupus erythematosus 29.4 IL2RA IL2 IFNA1 HLA-DRB1 HLA-DQB1 ALB
26 human immunodeficiency virus type 1 29.3 IL2 IFNA1 HLA-B HLA-A
27 rheumatoid arthritis 29.2 IL2RA IL2 HLA-DRB1 HLA-DQB1 HLA-B
28 autoimmune disease 29.1 STAT3 IL2RA IL2 IFNA1 HLA-DRB1 HLA-DQB1
29 acquired immunodeficiency syndrome 28.8 IL2RA IL2 IFNA1 HLA-B EPO ALB
30 aplastic anemia 28.3 TRB STAT3 KITLG IL2 HLA-DRB1 HLA-B
31 acquired pure red cell aplasia 13.0
32 diamond-blackfan anemia 12.1
33 diamond-blackfan anemia 1 11.9
34 lymphoproliferative syndrome, x-linked, 1 11.2
35 thymoma, familial 11.0
36 thymoma 11.0
37 lymphocytic leukemia 10.8
38 hemolytic anemia 10.7
39 leukemia, chronic lymphocytic 10.7
40 leukemia, b-cell, chronic 10.7
41 myasthenia gravis 10.7
42 anemia, autoimmune hemolytic 10.6
43 pulmonary fibrosis and/or bone marrow failure, telomere-related, 2 10.6
44 koro 10.6 OXA1L ALB
45 rheumatoid factor-negative juvenile idiopathic arthritis 10.6 IL2RA HLA-DRB1
46 lupus erythematosus 10.6
47 chronic kidney disease 10.6
48 calciphylaxis 10.6 EPO ALB
49 myelodysplastic syndrome 10.5
50 thrombocytopenia 10.5

Graphical network of the top 20 diseases related to Red Cell Aplasia:



Diseases related to Red Cell Aplasia

Symptoms & Phenotypes for Red Cell Aplasia

GenomeRNAi Phenotypes related to Red Cell Aplasia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance GR00327-A 8.92 EPO HLA-B HLA-DQB1 OXA1L

MGI Mouse Phenotypes related to Red Cell Aplasia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.63 ALB HLA-DQB1 IL2 IL2RA KITLG STAT3
2 liver/biliary system MP:0005370 9.43 ALB EPO HLA-DQB1 IL2 KITLG STAT3
3 respiratory system MP:0005388 9.1 EPO FLVCR1 HLA-DQB1 IL2 IL2RA STAT3

Drugs & Therapeutics for Red Cell Aplasia

Drugs for Red Cell Aplasia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 95)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Phenytoin Approved, Vet_approved Phase 4 57-41-0 1775
2
Sirolimus Approved, Investigational Phase 4 53123-88-9 6436030 5284616 46835353
3
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
4
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
5 Sodium Channel Blockers Phase 4
6 Diuretics, Potassium Sparing Phase 4
7 Cytochrome P-450 Enzyme Inducers Phase 4
8 Anticonvulsants Phase 4
9 Calcineurin Inhibitors Phase 4
10
Deferiprone Approved Phase 2, Phase 3 30652-11-0 2972
11
tannic acid Approved Phase 3 1401-55-4
12
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
13
Iron Approved, Experimental Phase 3 15438-31-0, 7439-89-6 23925 27284
14
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
15
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
16
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
17
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
18
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
19
Mycophenolic acid Approved Phase 3 24280-93-1 446541
20
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
21
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
22 Chelating Agents Phase 2, Phase 3
23 Iron Chelating Agents Phase 2, Phase 3
24 Ferric Oxide, Saccharated Phase 3
25 Nutrients Phase 3
26 Micronutrients Phase 3
27 Trace Elements Phase 3
28 Hematinics Phase 3
29 Epoetin alfa Phase 3 113427-24-0
30 Antifungal Agents Phase 3
31 Anti-Infective Agents Phase 3
32 Anti-Bacterial Agents Phase 3
33 Antibiotics, Antitubercular Phase 3
34 Hormone Antagonists Phase 3
35 Antiemetics Phase 3
36 Alkylating Agents Phase 3
37 Gastrointestinal Agents Phase 3
38 Anti-Inflammatory Agents Phase 3
39 Neuroprotective Agents Phase 3
40 glucocorticoids Phase 3
41 Peripheral Nervous System Agents Phase 3
42 Methylprednisolone Acetate Phase 3
43 Hormones Phase 3
44 Cyclosporins Phase 3
45 Antitubercular Agents Phase 3
46 Protective Agents Phase 3
47 Antineoplastic Agents, Hormonal Phase 3
48 Dermatologic Agents Phase 3
49 Antineoplastic Agents, Alkylating Phase 3
50 Antirheumatic Agents Phase 3

Interventional clinical trials:

(show all 46)
# Name Status NCT ID Phase Drugs
1 Research of Pure Red Cell Aplasia in Patients With Chronic Kidney Disease and in Use of Epoetin Alfa Produced by Immunobiological Technology Institute (Bio-Manguinhos) From Oswaldo Cruz Foundation (Bio-Manguinhos / Fiocruz) Unknown status NCT02648126 Phase 4
2 Phenytoin as an Augmentation for SSRI Failures: A Controlled Study Completed NCT00146237 Phase 4 phenytoin
3 Tacrolimus Treatment for Refractory Pure Red Cell Aplasia, a Prospective Study Recruiting NCT03540472 Phase 4 tacrolimus
4 Sirolimus Treatment for Refractory Pure Red Cell Aplasia, a Prospective Study Recruiting NCT03364764 Phase 4 Sirolimus
5 Tacrolimus Treatment for Refractory Autoimmune Cytopenia Not yet recruiting NCT03918265 Phase 4 Tacrolimus
6 Cohort Study to Determine the Long-Term Safety and Efficacy of Biogeneric Epoetin Treatment for Renal Anemia Unknown status NCT00238043 Phase 3 Biogeneric Epoetin
7 A Decisional Algorithm to Start Iron Chelation in Minimally Transfused Young Beta-thalassemia Major Patients Naive to Iron Chelation Therapy. A Comparative Randomized Prospective Study Unknown status NCT02173951 Phase 2, Phase 3 Deferiprone
8 A Randomized, Multi-Center, Open Label Trial to Establish the Therapeutic Equivalence Between GerEpo and Eprex® and to Determine the Long Term Safety Profile of GerEpo in Patients on Hemodialysis. Completed NCT00229099 Phase 3 GerEPO
9 Assessment of the Use of Intravenous Iron Sucrose to Maintain Haemoglobin Levels and Delay the Onset of Use of Erythropoietic Agents and/or Dialysis in Stage 3/4 Chronic Kidney Disease Completed NCT00202345 Phase 3 Iron sucrose
10 Randomized Controlled Trial Study of Anti-r-HuEpo Associated PRCA Treated by Cyclosporine and Mycophenolate Mofetil (MMF) Compared With Cyclophosphamide and Prednisolone Terminated NCT01288131 Phase 3 Cyclosporine combine with mycophenolate mofetil;Cyclophosphamide + pred
11 A Phase III Clinical Trial of PROCRIT (Epoetin Alfa) Versus Placebo in Women Undergoing Adjuvant Chemotherapy for Stage I, II or III Breast Cancer Terminated NCT00246597 Phase 3 epoetin alfa
12 Therapeutic Use of the Amino Acid Leucine in the Treatment of Transfusion-Dependent Diamond Blackfan Anemia Patients Unknown status NCT02386267 Phase 2 L-leucine
13 An Open-Label Study to Investigate the Efficacy and Safety of AF37702 Injection in the Treatment of Anemia Caused by Antibody-Mediated Pure Red Cell Aplasia in Patients With Chronic Kidney Disease Completed NCT00314795 Phase 2 Peginesatide
14 A Pilot Study of Recombinant Humanized Anti- Cluster of Differentiation Antigen 20 (Anti-CD20) Antibody (Rituximab) in Patients With Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan Anemia Completed NCT00229619 Phase 2 Rituximab
15 A Protocol to Allow Treatment With ICL670 for Patients With or at Risk of Life-threatening Complications of Transfusional Iron Overload Who Are Unable to Tolerate Other Iron Chelators Because of Documented Severe Toxicity Completed NCT01044186 Phase 2 ICL670
16 Allogeneic Mixed Chimerism Stem Cell Transplantation Utilizing In Vivo and In Vitro Campath for Hemoglobinopathies and Bone Marrow Failure Syndromes Completed NCT00004143 Phase 2 Campath, Chemo and/or TBI Allo SCT
17 Treatment of Diamond Blackfan Anemia With Antithymocyte Globulin and Cyclosporine A Completed NCT00001749 Phase 2 Antithymocyte globulin;Cyclosporine
18 The Erythropoietin NeuroProtective Effect: Assessment in CABG Surgery (TENPEAKS): A Randomized, Double-Blind, Placebo Controlled Proof-of-Concept Clinical Trial. Completed NCT00336466 Phase 2 Human recombinant erythropoietin
19 A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic Syndrome (MDS) Completed NCT00217594 Phase 2 Alemtuzumab (Campath)
20 A Randomized Trial of Recombinant Humanized Anti-IL-2 Receptor Antibody (Daclizumab) Versus Antithymocyte Globulin (ATG) to Treat the Cytopenia of Myelodysplastic Syndrome (MDS) Completed NCT00072969 Phase 2 Daclizumab
21 A Phase II Pilot Study of Nonmyeloablative Conditioning Hematopoietic Stem Cell Transplantation in Children With Sickle Cell Disease Who Have a Matched Related Major ABO-Incompatible Donor (Sickle-MAID) Recruiting NCT03214354 Phase 2 Alemtuzumab;Sirolimus
22 Phase I/II, Open Label Study to Determine Safety of Trifluoperazine (TFP) in Adults With Red Blood Cell Transfusion-Dependent Diamond Blackfan Anemia Recruiting NCT03966053 Phase 1, Phase 2 Trifluoperazine
23 Phase I/II, Open-Label Study to Determine Safety and Efficacy of Sotatercept (ACE-011) in Adults With Red Blood Cell Transfusion- Dependent Diamond Blackfan Anemia Recruiting NCT01464164 Phase 1, Phase 2 Sotatercept;Sotatercept with prednisone boost
24 A Phase II Trial of Haploidentical Allogeneic Stem Cell Transplantation Utilizing Mobilized Peripheral Blood Stem Cells Recruiting NCT03333486 Phase 2 Cyclophosphamide;Fludarabine Phosphate
25 Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia in Individuals With Higher Risk of Transplant Failure Recruiting NCT02105766 Phase 2 Alemtuzumab;Sirolimus;Cyclophosphamide;Pentostatin
26 A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy Recruiting NCT03076554 Phase 2 Avelumab
27 Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-Cells Recruiting NCT01174108 Phase 2
28 The Use of Novel Therapies to Reconstitute Blood Cell Production and Promote Organ Performance Using Bone Marrow Failure as a Model: a Pilot, Phase I/II Study of the Amino Acid Leucine in the Treatment of Patients With Transfusion-Dependent Diamond Blackfan Anemia Active, not recruiting NCT01362595 Phase 1, Phase 2 leucine
29 A Pilot Study of Recombinant Humanized Anti-Interleukin (IL-2) Receptor Antibody (Daclizumab) in Patients With Moderate Aplastic Anemia, Pure Red Cell Aplasia, or Diamond Blackfan Anemia Terminated NCT00001962 Phase 2 Daclizumab
30 A Phase II Study of Alemtuzumab in Autoimmune Cytopenias Terminated NCT00472433 Phase 2 Alemtuzumab
31 Screening Protocol and Longitudinal Study of Bone Marrow Failure Syndromes and Cytopenias Unknown status NCT00315419
32 Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases Unknown status NCT00006055 anti-thymocyte globulin;cyclophosphamide;cyclosporine;filgrastim;methylprednisolone;prednisone
33 An Active Safety Surveillance Plan to Prospectively Monitor the Incidence of Pure Red Cell Aplasia (PRCA) Among Patients Receiving Epoetin Alfa Therapy or Other Recombinant Erythropoietins Completed NCT00211029
34 An Active Safety Surveillance Plan to Conduct Serologic Testing for Anti-erythropoietin Antibodies and Prospectively Monitor the Incidence of Pure Red Cell Aplasia (PRCA) Among Patients Receiving Epoetin Alfa or Another Erythropoietin Completed NCT00210951
35 Observational, Multicenter Study of Subjects With Pure Red Cell Aplasia Associated With r-HuEPO Treatment Completed NCT00211042
36 Study of Allogeneic Bone Marrow Transplantation Using Matched, Related Donors in Patients With Nonmalignant Hematologic Disorders Completed NCT00005893 anti-thymocyte globulin;busulfan;cyclophosphamide
37 Retrospective Case-control Study of Risk Factors for Anti-erythropoietin Antibody Positive Pure Red Cell Aplasia Among Patients With Chronic Kidney Disease Receiving Epoetin Alfa Completed NCT00211068 No intervention
38 Stem Cell Transplantation (SCT) for Genetic Diseases Completed NCT00004378
39 A Prospective, Immunogenicity Surveillance Registry (PRIMS) to Estimate the Incidence of Erythropoietin Antibody-Mediated Pure Red Cell Aplasia Among Subjects With Chronic Renal Failure and Subcutaneous Exposure to Recombinant Erythropoietin Products Completed NCT00391287
40 Cytokine Gene Polymorphisms in Bone Marrow Failure Completed NCT00085670
41 Audit of the Effect of Changing From IV to SC Administration of Erythropoiesis Stimulating Agents in Haemodialysis Patients - Real Life Clinical Experience Completed NCT00382044 Eprex; Neorecormon; Aranesp
42 High-Tc Susceptometer to Monitor Transfusional Iron Overload (NSR Device) Completed NCT01241357
43 Diamond Blackfan Anemia Registry (DBAR) Recruiting NCT00106015
44 POST-AUTHORISATION SAFETY COHORT OBSERVATION OF RETACRIT (TM) (EPOETIN ZETA) ADMINISTERED SUBCUTANEOUSLY FOR THE TREATMENT OF RENAL ANAEMIA (PASCO II) Active, not recruiting NCT01543477
45 An Observational Study of Subjects Treated With Erythropoietin Receptor Agonists for Anemia Who Developed Anti-erythropoietin Antibodies Withdrawn NCT00210977 No intervention
46 Compassionate Use of the CliniMACS® CD34 Reagent System for Patients Requiring a Post Hematopoietic Stem Cell Transplant Boost of Donor Hematopoietic Stem Cells Withdrawn NCT01660347

Search NIH Clinical Center for Red Cell Aplasia

Genetic Tests for Red Cell Aplasia

Anatomical Context for Red Cell Aplasia

MalaCards organs/tissues related to Red Cell Aplasia:

41
Bone, Bone Marrow, T Cells, Kidney, B Cells, Liver, Myeloid

Publications for Red Cell Aplasia

Articles related to Red Cell Aplasia:

(show top 50) (show all 1931)
# Title Authors PMID Year
1
Anti-erythropoietin antibodies followed by endogenous erythropoietin production in a dialysis patient. 9 38
20091055 2010
2
Pure red cell aplasia associated with Good's syndrome accompanied by decreased stem cell factor production in the bone marrow. 9 38
20190468 2010
3
Rituximab therapy for pure red cell aplasia due to anti-epoetin antibodies in a woman treated with epoetin-alfa: a case report. 9 38
19830190 2009
4
Weekly administration of epoetin beta for chemotherapy-induced anemia in cancer patients: results of a multicenter, Phase III, randomized, double-blind, placebo-controlled study. 9 38
19164318 2009
5
[Erythropoiesis-stimulating agents in chronic kidney disease: which route of administration?]. 9 38
19255962 2009
6
Pure red cell aplasia due to follow-on epoetin. 9 38
18547998 2008
7
Epoetin-associated pure red cell aplasia: past, present, and future considerations. 9 38
18482185 2008
8
[Report of a case with pure red cell aplasia following recombinant human erythropoietin treatment]. 9 38
19099822 2008
9
Pure red cell aplasia induced by erythropoiesis-stimulating agents. 9 38
18178785 2008
10
Epoetin-induced pure red cell aplasia: diagnosis and treatment. 9 38
18089975 2007
11
A potent erythropoietin-mimicking human antibody interacts through a novel binding site. 9 38
17620453 2007
12
Hematide is immunologically distinct from erythropoietin and corrects anemia induced by antierythropoietin antibodies in a rat pure red cell aplasia model. 9 38
17662888 2007
13
[Pure red cell aplasia in patients treated with recombinant erythropoietin for anemia due to chronic renal disease]. 9 38
17571584 2007
14
Pure red cell aplasia caused by antibody to erythropoietin successfully treated by cyclosporine administration. 9 38
16947314 2007
15
Prevalence of anti-erythropoietin antibodies in hemodialysis patients without clinical signs of pure red cell aplasia. Comparison between hypo- and normoresponsive patients treated with epoetins for renal anemia. 9 38
17164586 2007
16
Erythropoietin dose requirements when converting from subcutaneous to intravenous administration among patients on hemodialysis. 9 38
16449549 2006
17
Efficacy prospective study of different frequencies of Epo administration by i.v. and s.c. routes in renal replacement therapy patients. 9 38
16249199 2006
18
Resistant pure red cell aplasia after allogeneic bone marrow transplantation with major ABO mismatch treated by purified CD34+ cell infusion. 9 38
16405438 2006
19
Epoetin alfa: basic biology and clinical utility in cancer patients. 9 38
16336085 2005
20
Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. 9 38
16099877 2005
21
Successful reintroduction of a different erythropoiesis-stimulating agent after pure red cell aplasia: relapse after successful therapy with prednisone. 9 38
16046510 2005
22
Incidence of recombinant erythropoietin (EPO) hyporesponse, EPO-associated antibodies, and pure red cell aplasia in dialysis patients. 9 38
16105053 2005
23
Adverse event issue management: what have we learnt from pure red cell aplasia (PRCA)? 9 38
16079325 2005
24
The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. 9 38
15882278 2005
25
Rapid resolution of EPO-induced pure red cell aplasia after a course of immunoadsorption therapy using protein A columns. 9 38
15957124 2005
26
Optimizing anaemia management with subcutaneous administration of epoetin. 9 38
15958820 2005
27
Factors influencing the immunogenicity of therapeutic proteins. 9 38
15958824 2005
28
What is antibody-mediated pure red cell aplasia (PRCA)? 9 38
15827056 2005
29
Assays for detecting and diagnosing antibody-mediated pure red cell aplasia (PRCA): an assessment of available procedures. 9 38
15827053 2005
30
Epoetin-associated pure red cell aplasia in patients with chronic kidney disease: solving the mystery. 9 38
15824129 2005
31
Antibody-mediated side effects of recombinant proteins. 9 38
15767028 2005
32
Epoetin-induced autoimmune pure red cell aplasia. 9 38
15938038 2005
33
Epoetin-induced pure red-cell aplasia (PRCA): preliminary results from the research on adverse drug events and reports (RADAR) group. 9 38
15792923 2005
34
Importance of biologic follow-ons: experience with EPO. 9 38
15792912 2005
35
Resistant pure red cell aplasia after allogeneic stem cell transplantation with major ABO mismatch treated by escalating dose donor leukocyte infusion. 9 38
15522068 2004
36
Re-challenging patients who developed pure red cell aplasia with epoetin: can it be done? 9 38
15496566 2004
37
Prolonged course of pure red cell aplasia after erythropoietin therapy. 9 38
15458518 2004
38
[Pure red cell aplasia as a complication of treatment with recombinant human erythropoietin]. 9 38
15690716 2004
39
Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: recommendations for minimization of risk. 9 38
15466278 2004
40
Expression, bioactivity, and clinical assessment of recombinant feline erythropoietin. 9 38
15524322 2004
41
Antierythropoietin antibody-induced pure red cell aplasia: posttransplant evolution. 9 38
15138876 2004
42
Pure red cell aplasia secondary to epoetin alpha responding to Darbepoetin alpha in a patient on peritoneal dialysis. 9 38
15284306 2004
43
Successful re-introduction of recombinant human erythropoietin following antibody induced pure red cell aplasia. 9 38
15252175 2004
44
Successful treatment of pure red cell aplasia with cyclosporin A and erythropoietin after thymectomy in a 88-year old woman. 9 38
15194553 2004
45
Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study. 9 38
15172775 2004
46
Pure red cell aplasia in patients with refractory anaemia treated with two different recombinant erythropoietins. 9 38
15009075 2004
47
Clinical efficacy and safety of recombinant canine erythropoietin in dogs with anemia of chronic renal failure and dogs with recombinant human erythropoietin-induced red cell aplasia. 9 38
14765736 2004
48
Evaluation of methods to detect and characterize antibodies against recombinant human erythropoietin. 9 38
15056991 2004
49
The detection of anti-erythropoietin antibodies in human serum and plasma. Part I. Validation of the protocol for a radioimmunoprecipitation assay. 9 38
14659922 2003
50
Pure red cell aplasia and anti-erythropoietin antibodies in patients treated with epoetin. 9 38
14608000 2003

Variations for Red Cell Aplasia

Expression for Red Cell Aplasia

Search GEO for disease gene expression data for Red Cell Aplasia.

Pathways for Red Cell Aplasia

Pathways related to Red Cell Aplasia according to GeneCards Suite gene sharing:

(show all 30)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.89 STAT3 KITLG IL2RA IL2 IFNA1 HLA-DRB1
2
Show member pathways
13.13 STAT3 KITLG IL2RA IL2 IFNA1 HLA-DRB1
3
Show member pathways
12.86 KITLG IL2RA IL2 IFNA1 HLA-B HLA-A
4 12.7 STAT3 KITLG IL2RA IL2 IFNA1 EPO
5
Show member pathways
12.54 TRB IL2RA IL2 HLA-DRB1 HLA-DQB1
6 12.47 STAT3 KITLG IL2RA IL2 IFNA1
7
Show member pathways
12.47 TRB STAT3 IL2RA IL2 HLA-DRB1 HLA-DQB1
8
Show member pathways
12.44 IFNA1 HLA-DRB1 HLA-DQB1 HLA-B HLA-A
9
Show member pathways
12.39 IL2 IFNA1 HLA-B HLA-A
10
Show member pathways
12.3 TRB IL2RA IL2 IFNA1 HLA-DRB1 HLA-DQB1
11
Show member pathways
12.29 IL2RA IL2 HLA-DRB1 HLA-DQB1
12
Show member pathways
12.29 STAT3 IL2RA IL2 IFNA1 EPO
13 12.14 IL2RA IL2 HLA-DRB1 HLA-DQB1 HLA-B HLA-A
14
Show member pathways
12.12 KITLG IL2RA IL2 IFNA1 HLA-B HLA-A
15 12.06 HLA-DRB1 HLA-DQB1 HLA-B HLA-A
16 12.03 HLA-DRB1 HLA-DQB1 HLA-B HLA-A
17
Show member pathways
11.94 STAT3 IL2RA IL2
18
Show member pathways
11.94 STAT3 KITLG IL2RA IL2
19 11.93 STAT3 KITLG ALB
20
Show member pathways
11.89 STAT3 IL2RA IL2
21 11.88 KITLG IL2RA IL2 EPO
22 11.83 TF STAT3 EPO
23 11.8 TRB HLA-DRB1 HLA-DQB1
24 11.75 STAT3 IL2RA IL2 IFNA1 EPO
25 11.64 KITLG IL2RA HLA-DRB1 HLA-DQB1 EPO
26
Show member pathways
11.56 IL2RA IL2 HLA-A
27 11.45 TF KITLG EPO
28 11.17 TRB IL2 HLA-DRB1
29
Show member pathways
11.15 TRB STAT3 IL2RA IL2 HLA-DRB1 HLA-A
30 10.9 STAT3 IL2RA IL2 HLA-DRB1

GO Terms for Red Cell Aplasia

Cellular components related to Red Cell Aplasia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.63 TF IL2RA HLA-DRB1 HLA-B HLA-A EPO
2 MHC class II protein complex GO:0042613 9.32 HLA-DRB1 HLA-DQB1
3 MHC class I protein complex GO:0042612 9.26 HLA-B HLA-A
4 ER to Golgi transport vesicle membrane GO:0012507 9.26 HLA-DRB1 HLA-DQB1 HLA-B HLA-A
5 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 8.92 HLA-DRB1 HLA-DQB1 HLA-B HLA-A

Biological processes related to Red Cell Aplasia according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.95 IL2RA IL2 HLA-DRB1 HLA-B HLA-A
2 negative regulation of apoptotic process GO:0043066 9.93 STAT3 KITLG IL2 EPO ALB
3 cytokine-mediated signaling pathway GO:0019221 9.87 STAT3 IL2RA IL2 IFNA1
4 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.69 STAT3 IL2 EPO
5 type I interferon signaling pathway GO:0060337 9.65 IFNA1 HLA-B HLA-A
6 immune response GO:0006955 9.63 IL2RA IL2 HLA-DRB1 HLA-DQB1 HLA-B HLA-A
7 positive regulation of T cell mediated cytotoxicity GO:0001916 9.62 HLA-B HLA-A
8 positive regulation of T cell differentiation GO:0045582 9.62 IL2RA IL2
9 positive regulation of Ras protein signal transduction GO:0046579 9.61 KITLG EPO
10 cell proliferation GO:0008283 9.61 STAT3 EPO
11 regulation of regulatory T cell differentiation GO:0045589 9.6 IL2RA IL2
12 erythrocyte maturation GO:0043249 9.59 FLVCR1 EPO
13 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.58 HLA-DRB1 HLA-DQB1
14 inflammatory response to antigenic stimulus GO:0002437 9.58 IL2RA HLA-DRB1
15 interleukin-2-mediated signaling pathway GO:0038110 9.56 IL2RA IL2
16 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.52 HLA-B HLA-A
17 antigen processing and presentation of endogenous peptide antigen via MHC class Ib GO:0002476 9.49 HLA-B HLA-A
18 negative regulation of lymphocyte proliferation GO:0050672 9.46 IL2RA IL2
19 protection from natural killer cell mediated cytotoxicity GO:0042270 9.43 HLA-B HLA-A
20 positive regulation of activated T cell proliferation GO:0042104 9.43 IL2RA IL2 EPO
21 humoral immune response mediated by circulating immunoglobulin GO:0002455 9.4 HLA-DRB1 HLA-DQB1
22 regulation of T cell homeostatic proliferation GO:0046013 9.37 IL2RA IL2
23 immunoglobulin production involved in immunoglobulin mediated immune response GO:0002381 9.32 HLA-DRB1 HLA-DQB1
24 interferon-gamma-mediated signaling pathway GO:0060333 9.26 HLA-DRB1 HLA-DQB1 HLA-B HLA-A
25 antigen processing and presentation GO:0019882 8.92 HLA-DRB1 HLA-DQB1 HLA-B HLA-A

Molecular functions related to Red Cell Aplasia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.26 KITLG IL2 IFNA1 EPO
2 MHC class II receptor activity GO:0032395 9.16 HLA-DRB1 HLA-DQB1
3 peptide antigen binding GO:0042605 8.92 HLA-DRB1 HLA-DQB1 HLA-B HLA-A

Sources for Red Cell Aplasia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....